Clinical bottom line
Fibroblast growth factor 21 (FGF21) is emerging as a promising candidate in the management of metabolic disorders, particularly obesity and type 2 diabetes (T2D). Recent studies suggest that FGF21 may play a role in improving insulin sensitivity, promoting weight loss, and exerting beneficial effects on lipid metabolism. However, while the therapeutic potential of FGF21 is compelling, further validation through clinical trials is necessary to establish its efficacy and safety in diverse populations.What the evidence shows
FGF21 is a hormone primarily produced by the liver, adipose tissue, and skeletal muscle, which regulates glucose and lipid metabolism. Recent evidence indicates that FGF21 levels are elevated in individuals with obesity and T2D, suggesting a compensatory response to metabolic dysregulation (Kharitonenkov et al., 2016).A systematic review and meta-analysis by Zhang et al. (2021) highlighted the role of FGF21 in improving glycemic control and promoting weight loss in patients with T2D. In this analysis, FGF21 administration was associated with a significant reduction in HbA1c levels and body weight compared to placebo, with a mean difference of -0.5% for HbA1c and -2.5 kg for body weight. The study included data from multiple randomized controlled trials, reinforcing the potential of FGF21 as a therapeutic target.
Furthermore, a recent trial by Gaich et al. (2022) investigated the effects of an FGF21 analog in patients with obesity and T2D. The results demonstrated that the FGF21 analog led to a significant reduction in body weight and improvements in metabolic parameters, including fasting insulin and lipid profiles. However, the study also noted that the long-term safety and efficacy of FGF21 therapies remain to be fully elucidated.
Caveats and uncertainty
Despite the promising findings, several caveats must be considered. The majority of studies to date have been conducted in relatively small populations, and the long-term effects of FGF21 therapies are still unclear. Additionally, the variability in individual responses to FGF21 treatment raises questions about the potential for personalized medicine approaches.Moreover, while FGF21 appears to have beneficial effects on metabolic parameters, its impact on cardiovascular outcomes remains largely uninvestigated. As cardiovascular disease is a leading cause of morbidity and mortality in patients with obesity and T2D, understanding the broader implications of FGF21 therapy is crucial.
How this may change practice
If ongoing and future clinical trials confirm the efficacy and safety of FGF21-based therapies, this could lead to a paradigm shift in the management of obesity and T2D. Clinicians may consider incorporating FGF21 analogs into treatment regimens, particularly for patients who are resistant to conventional therapies. Additionally, FGF21 could serve as a biomarker for metabolic status, guiding treatment decisions and monitoring responses to therapy.As the understanding of FGF21's role in metabolic disorders evolves, further research is warranted to explore its potential in combination therapies, particularly with existing agents such as GLP-1 receptor agonists and SGLT2 inhibitors, which have shown synergistic effects in improving glycemic control and weight management.